Document is current
Any future updates will be listed below
-
Authors
Patry, Christian https://orcid.org/0000-0002-1270-6508
Sauer, Lukas D. https://orcid.org/0000-0002-1340-9994
Sander, Anja
Krupka, Kai
Fichtner, Alexander https://orcid.org/0000-0002-9939-4059
Brezinski, Jolanda
Geissbühler, Yvonne https://orcid.org/0000-0001-8528-6818
Aubrun, Elodie
Grinienko, Anna
Strologo, Luca Dello https://orcid.org/0000-0002-8237-852X
Haffner, Dieter
Oh, Jun https://orcid.org/0000-0003-1846-675X
Grenda, Ryszard
Pape, Lars https://orcid.org/0000-0002-3635-6418
Topaloğlu, Rezan
Weber, Lutz T. https://orcid.org/0000-0003-4116-598X
Bouts, Antonia
Kim, Jon Jin
Prytula, Agnieszka
König, Jens https://orcid.org/0000-0002-9732-8656
Shenoy, Mohan
Höcker, Britta https://orcid.org/0000-0003-4131-2273
Tönshoff, Burkhard https://orcid.org/0000-0002-6598-6910
-
Funding
Funding for this research was provided by:
Novartis Pharma AG
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 26 May 2022
Revised: 2 September 2022
Accepted: 29 September 2022
First Online: 20 October 2022
Declarations
:
: B.T. is a consultant of Bristol-Myers Squibb, Chiesi, CSL Behring Biotherapies for Life, Novartis, and Vifor Pharma. L.T.W. is consultant of Alexion, Chiesi. He received lecture fees from Novartis, Chiesi and a reimbursement of travel cost from Astellas. The other authors declare that they have nothing to disclose and that there is no conflict of interest.
